Engbaek H C, Vergmann B, Bentzon M W
Eur J Respir Dis. 1984 Aug;65(6):411-8.
This is a prospective study of 36 patients with lung infections caused by M. avium/M. intracellulare. The division of the patients into 2 prognostic groups ("good"/"others"), and the guidelines for their treatment are based on a previous report (3). The criteria for the division were co-existing lung disease and dyspnoea on admittance. The patients in group "good" were treated with isoniazid, rifampicin and ethambutol, in group "others" these were supplemented with one or more drugs. As in the previous study (3), the prognosis was far better for group "good" than for group "others". The patients in group "good" should be treated with isoniazid, rifampicin and ethambutol, unless the course of disease is unsatisfactory. The mortality was high in group "others" and half of the deaths were related to mycobacteriosis. Some patients became culture negative and others showed decreasing numbers of bacteria, but the value of the supplementary drugs could not be proven.
这是一项对36例由鸟分枝杆菌/胞内分枝杆菌引起肺部感染患者的前瞻性研究。将患者分为2个预后组(“良好”/“其他”),其治疗指南基于先前的一份报告(3)。分组标准为入院时并存肺部疾病和呼吸困难。“良好”组患者接受异烟肼、利福平及乙胺丁醇治疗,“其他”组患者在此基础上补充一种或多种药物。与先前研究(3)一样,“良好”组的预后远优于“其他”组。“良好”组患者应接受异烟肼、利福平及乙胺丁醇治疗,除非疾病进程不理想。“其他”组死亡率较高,半数死亡与分枝杆菌病有关。部分患者培养转为阴性,其他患者细菌数量减少,但补充药物的价值未得到证实。